skip to content

Cambridge Academy of Therapeutic Sciences

 

Get in touch for more information or for support in applying for funding opportunities. 

Funding Opportunities


PhD Programme for Health Professionals - now recruiting for 2025 intake

Deadline - 5th November 2024

The University of Cambridge in collaboration with the University of East Anglia (UEA) and Wellcome Sanger Institute, is delighted to report that recruitment for the 2025 intake of the Health Professionals PhD Programme is now open. This programme is open to non-medical Health Professionals as well as medical, veterinary and dental graduates, with seven fellowships (funded by University and Wellcome Sanger Institute) available each year. This scheme is ideally suited to clinical health professionals of the highest calibre, seeking to pursue a successful academic career. If appropriate, pre-doctoral research placements in different research groups enables fellows to make an informed choice of supervisor and project, leading to a PhD.

Click here for further details about the programme.

Application details are available by clicking here.


BBSRC ICURe Explore (TRL2-6) in Partnership with NC3Rs

Deadline: 20th November 2024

Apply for funding to ‘get out of the lab’ and validate commercially promising bioscience-based ideas, research, science and technologies.

BBSRC ICURe Explore funds, trains and supports research teams from:

•    UK universities

•    BBSRC-funded institutes

•    Approved public sector research enterprises

This cohort is a collaboration between BBSRC and NC3Rs.

In this round, the programme will support market exploration for emerging technologies, products and services that offer the realistic possibility of replacing the use of specific in vivo models or refining animal studies in line with the NC3Rs mission that align with BBSRC’s standard ICURe scope.

Click here for more information.


Healthcare Technology Translation Partnership Scheme

Deadline - 27th November 2024

EPSRC has opened for the Healthcare Technology Translation Partnership Scheme 

 

This scheme aims to translate basic engineering and physical sciences research into impactful healthcare applications by partnering with clinical professionals and industry. 

The projects should address unmet clinical needs or significantly improve the current solutions, with funding of up to £1.5M available. EPSRC will fund 80% of the FEC.


BBSRC Follow-on Fund

Opportunity opens: 22nd January 2025

The BBSRC Follow-on Fund (FoF) is designed to support the translation of fundamental research into practical application, including commercialisation. They want to ensure that innovation arising from BBSRC-funded research has the best opportunity to create positive impacts for society.


Cancer Research Horizons Therapeutic Catalyst Award

Open ended

Cancer Research UK is uniting all their drug discovery and commercialization activity to form Cancer Research Horizons. An integral part of Cancer Research Horizons is an exciting and ambitious approach to driving therapeutic innovation. The new organization will be home to over 200 drug discovery scientists and will use cutting-edge capabilities to tackle the biggest challenges in discovering cancer drugs to help accelerate patient benefit.

To support this vision, the Therapeutic Catalyst Award is designed to kick-start exploratory drug discovery efforts in cancer, to validate and de-risk targets and technologies, and to position them for onward investment and progression. As a researcher, you can take your idea from bench to patients with a single funder and partner. Successful projects will receive up to £250,000 for up to 18 months. Informal enquiries can be directed to Matthew Farren and Neil Jones

______________________________________________________________________________________________________________________________________________________________________________________________

Project Proposals for the Functional Genomic Screening Laboratory

Open now

The Milner Therapeutics Institute recently announced a new partnership with AstraZeneca and the Medical Research Council (MRC) to establish a new state-of-the-art functional genomics screening laboratory (FGSL) based at the Milner Therapeutics Institute. The call for project proposals is now open!

The call is relevant to UK-based academics, small/medium-sized enterprises (SMEs) and pharma who have complex human in vitro models, such as organoids, co-culture models, etc., amenable to arrayed CRISPR screening. Through setting up collaborations with successful applicants, the FGSL will provide academic researchers, SMEs and pharma with access to arrayed functional genomics screening to better understand the biology represented by the model and where applicable, for target identification.

Please click here to find out more about the FGSL and call for proposals.